Phase I/II Trial of 211At-BC8-B10 in High-Risk Acute Leukemia and Myelodysplastic Syndrome
A phase I/II trial is evaluating the safety and dosing of 211At-BC8-B10 followed by donor stem cell transplant in patients with relapsed or refractory high-risk acute leukemia or myelodysplastic syndrome.